Voyager Therapeutics, Inc. develops genetic medicines and other neurotherapeutics for neurological diseases, with company updates focused on its CNS pipeline and delivery platforms. Recurring news covers the TRACER AAV capsid discovery platform, intravenous gene-therapy research, Voyager NeuroShuttle nonviral delivery work, and programs addressing Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, ALS, frontotemporal dementia and other central nervous system disorders.
Company announcements also cover tau-focused assets such as VY1706 and VY7523, small-molecule discovery collaboration targeting TDP-43 pathology, scientific conference presentations, and periodic financial and operating results. Voyager’s updates frequently connect pipeline spending, collaboration revenue, partner programs and balance-sheet resources with its genetic-medicine development strategy.
Voyager Therapeutics (Nasdaq: VYGR) has prioritized its therapeutic pipeline focusing on gene therapies for Alzheimer's, GBA1 Parkinson's, and SOD1 ALS, which have efficient paths to human proof of biology. The company reported a net loss of $19.1 million for Q2 2022, an improvement from $30.1 million in Q2 2021, aided by reduced R&D and G&A expenses. Voyager's cash position is strong, with $148.1 million as of June 30, 2022, providing a runway into 2024. Notably, Catherine J. Mackey, Ph.D., has been appointed to the Board of Directors.
Voyager Therapeutics (Nasdaq: VYGR) recently presented data at the Alzheimer’s Association International Conference highlighting novel antibodies that inhibit the spread of pathological tau in rodent models. The research demonstrates that these antibodies, which target specific forms of tau, could advance therapeutic options for tauopathies like Alzheimer's. Notably, vectorized antibody expression showed durability exceeding six months post-administration, with substantial efficacy in reducing tau pathology in mouse models. This research builds on prior findings about the potential of their blood-brain barrier-penetrating AAV capsids.
Voyager Therapeutics (Nasdaq: VYGR) will release its second quarter 2022 financial and operational results after the market closes on August 4, 2022. A live conference call and webcast will occur at 4:30 p.m. ET to discuss the results and provide a corporate update. Participants can join the call by dialing 1-833-634-2276 (domestic) or 1-412-902-4144 (international). A replay will be available for at least 30 days on its Investors website. Voyager Therapeutics focuses on developing AAV gene therapy treatments for serious diseases with its proprietary TRACER™ capsid platform.
Voyager Therapeutics (Nasdaq: VYGR) has appointed Catherine J. Mackey, Ph.D., to its Board of Directors, effective August 15, 2022. Dr. Mackey brings over 30 years of experience, notably at Pfizer, where she led R&D initiatives. Her expertise in strategic collaborations is expected to enhance Voyager's TRACER capsid discovery platform and pipeline development. CEO Al Sandrock emphasized the significance of Dr. Mackey's appointment at this pivotal moment for the company, aiming to leverage her knowledge for advancing AAV gene therapy solutions.
Voyager Therapeutics (Nasdaq: VYGR) recently presented promising preclinical data on its TRACER capsid platform at the ASGCT Annual Meeting. The novel AAV9-derived capsid, VCAP-102, showed significant enhancements in brain transduction—60-fold in non-human primates and 50-fold in mice—compared to conventional AAV9 capsids. The data indicate potential therapeutic benefits for CNS disorders, including GBA1, tauopathies, and SOD1 ALS. These advances support Voyager's ongoing gene therapy developments aimed at improving treatment for patients with severe neurological conditions.
Voyager Therapeutics (Nasdaq: VYGR) announced promising preclinical findings on its anti-HER2 antibody program at the ASGCT Annual Meeting. The TRACER AAV9 variant, VCAP-102, significantly reduced CNS tumor burden and enhanced survival in mouse models of HER2+ breast cancer, achieving a median survival of 129 days compared to 94 days for controls. Additionally, a novel AAV5-derived variant, VCAP-100, showed improved CNS transduction in non-human primates, indicating its potential for clinical development in CNS-targeted gene therapies.
Voyager Therapeutics (VYGR) presents significant advancements at the ASGCT Annual Meeting, showcasing preclinical data on its novel TRACER™ AAV capsids, demonstrating enhanced CNS tropisms and cross-species translatability. Key highlights include a license agreement with Novartis, providing $54 million upfront for potential CNS applications. The company reported Q1 2022 revenues of $0.7 million, down from $6.5 million YoY, and a net loss of $21.3 million. Strong cash position of $166.8 million expected to fund operations into 2024.
Voyager Therapeutics (NASDAQ: VYGR) has announced nine presentations for the upcoming ASGCT 2022 meeting from May 16-19 in Washington, D.C. Highlights include new findings on TRACER™-generated AAV capsids, focusing on glial cell tropism, and a novel vectorized antibody approach targeting metastatic breast cancer. Notable presentations will cover improvements in CNS-targeted AAV vectors and gene therapies for ALS and other neurological diseases. CEO Al Sandrock emphasized the importance of these data in shaping Voyager's pipeline strategy.
Voyager Therapeutics announces the appointment of Dr. Alfred W. Sandrock, Jr. as CEO, succeeding Michael Higgins who served as interim CEO since June 2021. Dr. Sandrock, a prominent neuroscientist with a strong background in therapeutic development, aims to enhance Voyager's efforts in AAV gene therapy. His leadership is expected to drive advancements in Voyager's TRACER™ capsid discovery platform, potentially broadening applications for various diseases. The company is focused on achieving human proof of concept for its internal pipeline and has established licensing agreements with major pharmaceutical firms.
Voyager Therapeutics, Inc. (Nasdaq: VYGR) has announced a license option agreement with Novartis for access to its TRACER™ AAV capsids, targeting three CNS applications and options for two additional targets. This deal, alongside a previous Pfizer agreement, extends Voyager's cash runway into 2024 with total upfront payments of $84 million. The company reported a net income of $5.7 million for Q4 2021, improving from a loss in Q4 2020. However, the full year net loss was $71.2 million, primarily due to terminated collaborations. Leadership changes include the appointment of Al Sandrock, Jr. to the Board.